DON'T BUY
New drug failed and generic drug companies getting into their products. Market share will probably shrink.
DON'T BUY
Management has zero credibility. Next year will be brutal. Their technology is outdated.
DON'T BUY
Trading below their cash holdings. Burning cash, but not much. Sales will stay down. Can't see any growth.
HOLD
Risky. Industry is unstable. Wait for techs to find a bottom.
PAST TOP PICK
( A "high risk" TOP pick on Mar 18. Down 30%) Have three businesses that are worth more than the stock is trading at. If they can sell CIT for a reasonable price, some of the issues will disappear. Remaining businesses will be good. RISK/REWARD is still
BUY ON WEAKNESS
Have $6 a share in cash. Expects $2 in earnings over the next few years. At a good price for a long term hold, but could drop lower. Try to buy in the $40's, but only a bit at a time.
WEAK BUY
Company has been doing well. Revenues growing @ 10%, earnings @ 20%. Trading at 19 X. Great long term.
WEAK BUY
Have to see power demands grow. If economy turns, it could do well.
BUY ON WEAKNESS
Has not been growing for 3 years. Would pay 18/20 multiple on the stock/earmings. Buy at $25.
DON'T BUY
A lot of competition. Have a lot of cash, but are losing money.
HOLD
Doing well. Taking business from Nokia.Very competitive.
DON'T BUY
Profitibility is heading down.
DON'T BUY
There could be more civil litigations.
DON'T BUY
Economically sensitive so customers are not buying.
PAST TOP PICK
A top pick on Mar 18. Up around 7 or 8%) Still likes.